Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) has announced that it will report its financial results for Q4 and the full year of 2022 on February 14, 2023, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, which will be available via webcast on the company's website. Adaptive is focused on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment. The company aims to leverage its proprietary immune medicine platform to address various diseases, including cancer and autoimmune disorders, emphasizing individualized patient care.

Positive

• Scheduled financial results announcement for Q4 and full year 2022.
• Conference call and webcast planned for investor engagement.

Negative

• None.

SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 14, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Mary Pat Lancelotta
206-600-6702
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its Q4 and full year 2022 financial results?

Adaptive Biotechnologies will report its financial results on February 14, 2023, after market close.

What time is the conference call for Adaptive Biotechnologies' financial results?

The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on February 14, 2023.

Where can I listen to the Adaptive Biotechnologies webcast?

The webcast will be available on the 'Investors' section of Adaptive Biotechnologies' website.

What is the main focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases.